Lynparza (Olaparib)

Lynparza is a medicine used to treat some ovarian, breast, pancreatic and prostate cancers, especially in people with a BRCA gene change. It is taken as a pill by mouth. It works by stopping cancer cells from fixing their damaged DNA, so they die.

Brand names:Lynparza
Medication

What people taking Lynparza (Olaparib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lynparza (Olaparib) for Ovarian Tumors?

NameHow it went

About Lynparza (Olaparib)

What It's For

Olaparib, sold as Lynparza, is a prescription cancer medicine taken as a tablet. It belongs to a group called PARP inhibitors and is used for certain ovarian, breast, pancreatic and prostate cancers in adults. It is a targeted treatment rather than a general one: it is offered only when testing shows the cancer has a specific weakness in how it repairs DNA, most often a change (mutation) in the BRCA1 or BRCA2 genes. Depending on the cancer, that change may be inherited (found in a blood or saliva test) or present only in the tumor. In ovarian cancer, which here includes fallopian tube and primary peritoneal cancer, olaparib is mainly a maintenance treatment. It is started after platinum-based chemotherapy has shrunk or cleared the cancer, to keep it from returning or growing for longer. People with a BRCA mutation can take it alone, either after their first chemotherapy or after treatment for a recurrence. People whose tumor tests as HRD-positive (homologous recombination deficiency, a broader sign of faulty DNA repair) may take it alongside bevacizumab (Avastin), an infused drug that limits a tumor's blood supply. For breast cancer, olaparib is used in people with an inherited BRCA mutation whose cancer is HER2-negative, meaning it is not driven by the HER2 growth protein. It can be given for one year after surgery and chemotherapy for high-risk early breast cancer, to lower the chance of the cancer coming back, or used to treat breast cancer that has spread after earlier chemotherapy. In pancreatic cancer that has spread, it is a maintenance option for people with an inherited BRCA mutation whose cancer stayed under control through at least 16 weeks of platinum chemotherapy. For prostate cancer that has spread and keeps growing despite testosterone-lowering treatment (called metastatic castration-resistant prostate cancer), olaparib can be used alone when the tumor carries a mutation in BRCA or one of several related repair genes and the cancer has progressed after enzalutamide (Xtandi) or abiraterone (Zytiga). It is also approved together with abiraterone and prednisone (or prednisolone) when the cancer has a BRCA mutation.

How It Works

Cells constantly repair small breaks in their DNA. One set of enzymes, called PARP, fixes minor single-strand breaks, while a separate system that depends on genes such as BRCA1 and BRCA2 fixes more serious double-strand damage. Healthy cells have both systems, so they can usually cope when one is blocked. Olaparib blocks PARP and also traps it on the DNA, which leaves unrepaired damage behind. In cancer cells that have already lost their BRCA-based repair system, this damage builds up until the cells can no longer divide and die. That is why the drug works best in cancers with these specific genetic changes, and why testing comes before treatment. In prostate cancer, PARP also plays a part in the signaling that drives tumor growth, which helps explain why olaparib is paired with abiraterone in some people.

Dosage & Administration

Lynparza comes as tablets, usually taken twice a day, with or without food. The standard adult dose is 300 mg twice daily, though many people end up on a lower dose to manage side effects, and the dose is also lowered for moderate kidney impairment or when a strongly interacting medicine cannot be avoided. Swallow the tablets whole; do not chew, crush, dissolve or split them. If a dose is missed, skip it and take the next one at the usual time rather than doubling up. How long treatment lasts depends on why it is being used. After first-line chemotherapy for ovarian cancer, it is usually given for up to two years, and people whose scans show no remaining cancer at that point generally stop. For high-risk early breast cancer it is taken for one year. In other situations it continues as long as it keeps the cancer under control and side effects remain manageable. Men taking it for prostate cancer continue their testosterone-lowering treatment unless they have had both testicles removed.

Side Effects

Nausea and tiredness are the most common side effects; more than half of people in clinical trials had them. Vomiting, diarrhea, loss of appetite, headache, a changed sense of taste, dizziness and indigestion are also common. Nausea is often mild to moderate and tends to be worst early on; anti-nausea medicine can be prescribed, so it is worth reporting rather than enduring. Low blood counts are frequent too, especially anemia (a shortage of red blood cells), which can add to fatigue and sometimes needs a dose break, a lower dose or a transfusion. A small number of people (about 1 in 100 in pooled trials) have developed myelodysplastic syndrome or acute myeloid leukemia, serious bone marrow cancers that were often fatal. Most had received earlier chemotherapy. Blood counts are checked before starting and monthly during treatment partly to catch this. Contact the care team promptly about lasting weakness or tiredness, fevers or frequent infections, easy bruising or bleeding, blood in the urine or stool, or unexplained weight loss. Olaparib can also cause lung inflammation (pneumonitis), which is uncommon but can be fatal. New or worsening cough, shortness of breath, wheezing or fever should be reported to the care team right away. Blood clots in the legs or lungs occur more often than with placebo, particularly in prostate cancer (about 8 in 100 men in trials). Report pain or swelling in one leg or arm promptly; sudden chest pain, sudden breathlessness or a racing heart can mean a clot has reached the lungs and needs emergency care. Rarely, the drug injures the liver, so liver blood tests are checked during treatment; contact the care team right away about yellowing of the skin or eyes, dark urine or new discomfort in the upper abdomen.

Interactions & Warnings

Olaparib is broken down in the liver by an enzyme called CYP3A, so medicines that slow or speed up that enzyme change how much of the drug stays in the body. Some antifungal drugs (such as itraconazole), certain antibiotics (such as clarithromycin) and some HIV medicines can raise olaparib levels and increase side effects. Others, including the seizure medicines carbamazepine and phenytoin, the tuberculosis antibiotic rifampin and the herbal supplement St. John's wort, can lower levels and make it less effective. These combinations are generally avoided, or the olaparib dose is reduced. Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice (often used in marmalade), which act the same way. Give the care team and pharmacist a full list of prescriptions, over-the-counter medicines and supplements, and check before starting anything new. Olaparib also adds to the effect on blood counts of other cancer treatments that suppress the bone marrow. Olaparib can harm a developing baby and cause pregnancy loss. Women who could become pregnant are checked for pregnancy before starting and should use effective contraception during treatment and for 6 months after the last dose. Men with a partner who is pregnant or could become pregnant should use effective contraception during treatment and for 3 months afterward, and should not donate sperm during that time. Breastfeeding is not recommended during treatment or for 1 month after the last dose.

What to Expect

Olaparib is a long-term daily medicine, and the first months set the pattern. Blood tests are done before starting and about monthly afterward to check blood counts and liver function, along with regular scans or tumor markers to see whether the cancer is staying under control. Treatment usually begins only once blood counts have recovered from earlier chemotherapy. Dose interruptions and reductions are common, often because of anemia or nausea, and are a normal way of keeping treatment going rather than a sign that it has failed. In maintenance treatment, the aim is that nothing much happens: the cancer stays quiet for longer than it otherwise would. In the large trials, olaparib clearly delayed cancer growth or return compared with a placebo, and in high-risk early breast cancer it also helped people live longer. Whether it extends overall survival has been less clear in some other settings, such as recurrent ovarian cancer, and individual responses vary widely. If scans show the cancer growing, or side effects cannot be controlled with dose changes, the oncologist will talk about stopping and what comes next.

Questions to Ask Your Doctor

  1. 1.Which test result makes me eligible for olaparib, and was my mutation inherited, which could matter for my relatives?
  2. 2.What is the goal of olaparib for me, and how long do you expect me to take it?
  3. 3.How will we handle nausea, fatigue or anemia if they become a problem, and when would you lower my dose?
  4. 4.Do any of my current medicines or supplements interact with olaparib, and should I check with you before starting new ones?
  5. 5.Which symptoms should I call about right away, and how do I reach the team outside office hours?

Last reviewed • Oct 2026

Educational content, not medical advice.